Polymorphic form of atorvastatin calcium

Details Polymorphic form of atorvastatin calcium Polymorphic form of atorvastatin calcium

2008-07-11

2010-06-08

Stockton, Laura L. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S423000

Reexamination Certificate

active

07732623

ABSTRACT:
The present invention relates to atorvastatin calcium, a useful agent for lowering serum cholesterol levels. New atorvastatin calcium Form V, processes for preparing the new form, and pharmaceutical compositions and dosage forms containing the new form are disclosed.

REFERENCES:
patent: 4137322 (1979-01-01), Endo et al.
patent: 4681893 (1987-07-01), Roth
patent: 5003080 (1991-03-01), Butler et al.
patent: 5273995 (1993-12-01), Roth
patent: 5298627 (1994-03-01), Butler et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5969156 (1999-10-01), Briggs et al.
patent: 6087511 (2000-07-01), Lin et al.
patent: 6121461 (2000-09-01), McKenzie
patent: 6476235 (2002-11-01), Butler et al.
patent: 6528661 (2003-03-01), Niddam et al.
patent: 6531507 (2003-03-01), Pflaum et al.
patent: 6600051 (2003-07-01), Tully
patent: 6605636 (2003-08-01), Aronhime et al.
patent: 6605728 (2003-08-01), O'Connell et al.
patent: 6605729 (2003-08-01), Byrn et al.
patent: 6806290 (2004-10-01), Pflaum et al.
patent: 7144916 (2006-12-01), Aronhime et al.
patent: RE39502 (2007-03-01), Fox et al.
patent: 2002/0099224 (2002-07-01), Niddam et al.
patent: 2002/0115709 (2002-08-01), Aronhime et al.
patent: 2003/0114686 (2003-06-01), Van Der Schaaf et al.
patent: 2003/0212279 (2003-11-01), Tessler et al.
patent: 2003/0216584 (2003-11-01), Aronhime et al.
patent: 2004/0054193 (2004-03-01), Byrn et al.
patent: 2004/0077708 (2004-04-01), Grahek et al.
patent: 2004/0106670 (2004-06-01), Blatter et al.
patent: 2004/0220255 (2004-11-01), Van Der Schaaf et al.
patent: 2004/0242899 (2004-12-01), Reddy et al.
patent: 2005/0209306 (2005-09-01), Jegorov et al.
patent: 0 247 633 (1987-12-01), None
patent: 0 409 281 (1991-01-01), None
patent: P9900678 (1999-07-01), None
patent: WO 94 16693 (1994-08-01), None
patent: WO 97/03958 (1997-02-01), None
patent: WO 97 03958 (1997-02-01), None
patent: WO 97/03959 (1997-02-01), None
patent: WO 97/03960 (1997-02-01), None
patent: WO 00/71116 (2000-11-01), None
patent: WO 01/28999 (2001-04-01), None
patent: WO 01/36384 (2001-05-01), None
patent: WO 01/42209 (2001-06-01), None
patent: WO 01/44180 (2001-06-01), None
patent: WO 01/44181 (2001-06-01), None
patent: WO 02/41834 (2002-05-01), None
patent: WO 02/43732 (2002-06-01), None
patent: WO 02/051804 (2002-07-01), None
patent: WO 02/057228 (2002-07-01), None
patent: WO 02/057229 (2002-07-01), None
patent: WO 02/059087 (2002-08-01), None
patent: WO 02/083637 (2002-10-01), None
patent: WO 02/083638 (2002-10-01), None
patent: WO 03/004470 (2003-01-01), None
patent: WO 03/011826 (2003-02-01), None
patent: WO 03/016317 (2003-02-01), None
patent: WO 03/018547 (2003-03-01), None
patent: WO 03/050085 (2003-06-01), None
patent: WO 03/070702 (2003-08-01), None
patent: WO 2004/022053 (2004-03-01), None
patent: WO 2004/050618 (2004-06-01), None
Thomas M.A. Bocan et al. “Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation”, Atheroselerosis 111 (1994) pp. 127-142.
Thomas M.A. Bocan, Declaration Under Rule 132, dated Dec. 2, 1998, filed in U.S. Appl. No. 08/945,812; 2 pages.
Stephen R. Byrn, Declaration Under Rule 132, dated Nov. 25, 1998, filed in U.S. Appl. No. 08/945,812; 3 pages.
David J. W. Grant, Theory and Origin of Polymorphism, in Drugs of the Pharmaceutical Sciences, vol. 95, Polymorphism in Pharmaceutical Solids, Chapter 1, (Harry G. Brittain ed., 1999).
K.L. Baumann et al., “The Convergent Synthesis of CI-981, an Optically Active, Highly Potent, Tissue Selective Inhibitor of HMG-CoA Reductase,” Tetrahedron Letters, vol. 33, No. 17 (1992) pp. 2283-2284.
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th Ed. (1996) pp. 879-881.
Cheronis, Semimicro Experimental Organic Chemistry, pp. 31-49.
Haleblian & Crone, 1969. J. Pharm. Sci.58:911-929.
G. Michael Wall, “Pharmaceutical Applications of Drug Crystal Studies”, Pharmaceutical Manufacturing (Feb. 1986) pp. 33-42.
U.S. Pharmacopia #23, p. 1843, 941 X-Ray Diffraction, 1995.
McCrone W.C., “Polymorphism”, Physics and Chemistry of the Organic Solid State, vol. 2, 1965, pp. 725-767.
Caira M.R., “Crystalline Polymorphism of Organic Compounds” Topics in Current Chemistry, Springer, Berlin, DE, vol. 198, 1998, pp. 163-208.
Graul A., et al., “Atorvastatin Calcium” Drugs of the Future, Barcelona, ES, vol. 22, No. 9, 1997, pp. 956-968.
Guillory, J.K.: “in Polymorphism in Pharmaceutical Solids (Brittain, H.G., ed.)”, 1999, Marcel Dekker, Inc., New York, Basel, pp. 183-226.
Hancock B.C., et al., “Characteristics and Significance of the Amorphous State in Pharmaceutical Systems”, Journal of Pharmaceutical Sciences, American Pharmaceutical Association, Washington, U.S., vol. 86, No. 1, Jan. 1997, pp. 1-12.
Walter DeGruyter, Concise Encyclopedia Chem. (1993), Berlin, NY, Title page and copyright page only.
Bernstein, J. (2002) “Polymorphism in Molecular Crystals,” pp. 1-28 and 240-256 (Clarendon Press, Oxford, U.K., pub.).
Brittain, H.G. ed.(1999) “Methods for the Characterization of Polymorphs and Solvates,” pp. 227-240 in “Polymorphism in Pharmaceutical Solids” (Brittain, H.G., ed., Marcel Dekker, Inc., New York, NY, pub.).
Brittain, H.G., ed. (1999) “Methods for the Characterization of Polymorphs and Solvates,” pp. 1-3, 178-179, 185-187, 219, 236 in “Polymorphism in Pharmaceutical Solids” (Marcel Dekker, Inc., New York, NY, pub.).
Brittain, H.G., ed. (1999) “Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids,” pp. 183-226 in “Polymorphism in Pharmaceutical Solids” (Marcel Dekker, Inc., New York, NY, pub.).
Brittain, H.G., ed. (1999) “Methods for the Characterization of Polymorphs and Solvates,” pp. 348-361 in “Polymorphism in Pharmaceutical Solids” (Marcel Dekker, Inc., New York, NY, pub.).
Byrn, S.R., et al., (1999) “Drugs as Molecular Solids,” pp. 3-5 in “Solid-State Chemistry of Drugs,” 2nd ed., (SSCI, Inc., West Lafayette, IN, pub.).
Byrn, S.R., et al. (1999) “The X-Ray Powder Diffraction Method,” pp. 59-63 in “Solid-State Chemistry of Drugs” 2nd ed., (SSCI, Inc., West Lafayette, IN, pub.).
Chen, B., et al., “Synthesis of Deuterium-Labeled Atorvastatin and its Metabolites for Use as Internal Standards in a LC/MS/MS Method Developed for Quantitation of the Drug and its Metabolites in Human Serum,” Journal of Labeled Compounds and Radiopharmaceuticals 43 (2000) pp. 261-270.

Affiliated with

Also associated with

Rating

Polymorphic form of atorvastatin calcium does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polymorphic form of atorvastatin calcium, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphic form of atorvastatin calcium will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4227878